Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
First Claim
1. A method of treating schizophrenia in a patient, comprising administering to a patient having schizophrenia a therapeutically effective amount of (a) N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof, and (b) risperidone.
3 Assignments
0 Petitions
Accused Products
Abstract
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson'"'"'s Disease, related human neurodegenerative diseases, and psychosis.
-
Citations
24 Claims
-
1. A method of treating schizophrenia in a patient, comprising administering to a patient having schizophrenia a therapeutically effective amount of (a) N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof, and (b) risperidone.
- View Dependent Claims (4, 7, 10, 13, 14, 15, 22)
-
2. A method of treating schizophrenia in a patient, comprising administering to the patient having schizophrenia a therapeutically effective amount of (a) N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof, and (b) haloperidol.
- View Dependent Claims (5, 8, 11, 16, 17, 18, 23)
-
3. A method for reducing an amount of haloperidol or risperidone effective to treat psychosis in a schizophrenic patient, the method comprising administering a therapeutically effective amount of N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′
- -(4-(2-methylpropyloxy)phenylmethyl)carbamide, or a pharmaceutically acceptable salt thereof, to the schizophrenic patient with psychosis being treated with haloperidol or risperidone.
- View Dependent Claims (6, 9, 12, 19, 20, 21, 24)
Specification